RubrYc Therapeutics Announces A Research Collaboration And License Option Agreement With Zai Labs
SAN CARLOS, Calif., April 14 (Bernama-BUSINESS WIRE) — RubrYc Therapeutics, Inc., a pre-clinical biotherapeutics company developing epitope selective therapies, today announced that it has entered into a research collaboration and license option agreement with Zai Labs, Inc. for the use of RubrYc’s Meso-scale Engineered Molecules (MEMs) platform, to identify monoclonal antibodies…

